Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tumor neoantigenicity metric improves prediction of response to immunotherapy

Publish date:: February 22, 2020

Key clinical point: Compared with existing metrics, the Cauchy-Schwarz index of neoantigens (CSiN) score may be better at predicting response to immunotherapy among patients with immunogenic cancer.

Major finding: There was a significant positive association between higher CSiN scores and better response among melanoma patients who received anti–CTLA-4 therapy (P = .009), patients with clear cell renal cell carcinoma treated with anti-PD-1/PD-L1 therapy (P = .036), and patients with non–small cell lung cancer treated with checkpoint inhibitors (P = .015).

Study details: A retrospective study of 2,479 cancer patients.

Disclosures: The study was funded by the National Institutes of Health, the Cancer Prevention Research Institute of Texas, and the American Cancer Society. The investigators reported no conflicts of interest.

Citation:

Lu et al. Sci Immunol. 2020 Feb 21. doi: 10.1126/sciimmunol.aaz3199.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Immunotherapy

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Personalized cancer vaccine may enhance checkpoint inhibitor activity,

New registry focuses on rheumatic immune-related AEs of cancer therapy,

Tumor neoantigenicity metric improves prediction of response to immunotherapy,

New Toxicity Subscale Measures QOL in Cancer Patients on Checkpoint Inhibitors,